

# Anti-CyclinA [AT10.2]

**Catalogue number:** 151261

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:** Julian Gannon

**Institute:** Cancer Research UK, London Research Institute: Clare Hall Laboratories

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-CyclinA [AT10.2]

**Alternate name:** CCNA1; Cyclin A1; Testicular Tissue Protein Li 34; CT146

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** Cyclins bind to and regulate the activity of the Cyclin Dependent Protein Kinases (CDKs). Cyclin A is involved in the regulation of the cell cycle and is essential for progression through S phase. Cyclin A protein is absent in cells prior to S-phase, during which its levels increase and peak. Cyclin A is a marker for actively proliferating cells and for cells in S phase. E23.1 is extremely sensitive for immunoblotting Cyclin A.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG1

**Reactivity:** Human

**Selectivity:**

**Host:** Mouse

**Immunogen:** Recombinant Human Cyclin A

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** Cyclin A

**Target alternate names:**

**Target background:** Cyclins bind to and regulate the activity of the Cyclin Dependent Protein Kinases (CDKs). Cyclin A is involved in the regulation of the cell cycle and is essential for progression through S phase. Cyclin A protein is absent in cells prior to S-phase, during which its levels increase and peak. Cyclin A is a marker for actively proliferating cells and for cells in S phase.

**Molecular weight:**

**Ic50:**

## Applications

**Application:** IHC ; IP ; WB

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:** 1 mg/ml

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:** PBS with 0.02% azide

**Storage conditions:** -15° C to -25° C

**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:**

## References

**References:** Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744. ; DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. ; Hui et al. 2002. Clin Cancer Res. 8(8):2595-604. PMID: 12171890. ; Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. ; Beasley et al. 2002. Cancer Res. 62(9):2493-7. PMID: 11980639. ; Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. ; Talks et al. 2000. Am J Pathol. 157(2):411-21. PMID: 10934146. ; The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. ; Wiesener et al. 1998. Blood. 92(7):2260-8. PMID: 9746763. ; Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.

CancerTools.org